SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a massive, unsolicited $56 billion bid to acquire eBay, a move that has ignited intense debate over potential stock dilution versus the strategic ambition to build an e-commerce rival to Amazon. The community remains deeply polarized, with bulls viewing the play as a bold, long-term transformational move, while vocal bears and skeptics are heavily criticizing the CEO's confrontational media presence and the logistical hurdles of the proposed financing.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing intense investor interest driven by a massive short squeeze setup, characterized by high borrowing costs and low share availability. The community is focused on the upcoming earnings report as a major catalyst for momentum, with many bulls actively discouraging selling and urging a long-term hold to maximize pressure on short sellers.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is experiencing extreme volatility driven by a prospectus filing that registers a large volume of existing Class B shares for potential resale, which the community is debating as either a standard liquidity event or a sign of an impending supply overhang. Investors are actively discussing the technical merits of the company's photonic quantum approach, while many express mixed sentiment over the stock's speculative nature and the rapid price fluctuations following the registration news.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively buy into a structural memory supercycle, with community members highlighting that AI infrastructure demand for DRAM and HBM is decoupling the stock from traditional cyclical patterns. Bullish sentiment remains dominant as market participants point to supply shortages and major hyperscale partnerships as the primary drivers, with many actively discussing the potential for a massive rerating as the stock approaches new highs.

Elong Power Holding Ltd. engages in the research and development, manufacturing, sales and service of high-power lithium-ion batteries for electric vehicles and construction machinery, as well as large-capacity, long-cycle lithium-ion batteries for energy storage systems. The company was founded on August 18, 2023 and is headquartered in Ganzhou, China.

Elong Power Holding Ltd. - Ordinary Shares - Class A

Elong Power Holding Limited

Elong Power Holding Limited (ELPW) is experiencing high-volume volatility and active short-squeeze speculation, with the community closely tracking the ticker alongside other low-float, China-based small caps. Retail traders are intensely focused on key price levels and resistance breakouts while debating the sustainability of the move versus potential downside risk.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Cns Pharmaceuticals is experiencing intense volatility and volume as investors react to a private placement financing announcement, fueling intense community debates about potential squeezes versus long-term dilution concerns. Retail traders are closely monitoring the stock's tight float and rapid price swings, with active discussions centered on technical breakout levels and the company's shifting strategic focus.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is currently a focal point for investors as the community anticipates critical upcoming data regarding biomarker analysis and potential FDA accelerated approval pathways for its ALS candidate, CNM-Au8. Discussion is heavily focused on the company's regulatory roadmap, the impact of recent insider selling, and the broader context of how emerging biomarker evidence could influence the stock's long-term valuation.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is experiencing significant volatility driven by heavy short interest and a low-float structure, with community discussions largely centered on aggressive short squeeze potential and speculative trading dynamics. Investors are debating the sustainability of the price action, frequently drawing parallels to past momentum plays while others warn of the risks associated with rapid, news-sparse price swings.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following an unsolicited takeover proposal from GameStop, which has fueled intense community debate over the feasibility of the deal and the potential for a massive acquisition strategy. Market participants are actively scrutinizing the financing requirements and the viability of a cash-and-stock offer that significantly exceeds GameStop's current market valuation.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors rally behind the upcoming April 30 PDUFA date for the label expansion of Auvelity into Alzheimer's disease agitation. The community is heavily focused on the stock's multi-year growth trajectory, institutional accumulation, and the potential for Auvelity to become a dominant CNS blockbuster, with many discussing its prospects as a prime acquisition target for big pharma.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Lisata...

Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs for $5.00 per share + $1.00 CVR.read more...

Lisata Therapeutics Agrees To Be Taken Private By Kuva Labs

(RTTNews) - Lisata Therapeutics Inc. (LSTA) announced that it has entered into a definitive agreement to be acquired by Kuva Labs Inc., a privately held company. Under the terms of the merger...

Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Feb. 11, 2026 Insiders may stand to...

Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their...

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA...

LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lisata Therapeutics, Inc. (NASDAQ: LSTA) to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable...

<ul class="summary-bullets"><li>Lisata and Kuva intend to enter into a definitive purchase agreement before Feb 27.</li><li>Under the deal, Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash.</li><li>Lisata shareholders will also be entitled to up to $2 per share contingent upon the achievement of certain pre-specified milestones.</li></ul>&nbsp;Shares of Lisata Therapeutics, Inc. (LSTA) soared 88% on Wednesday after the company said that it has a buyout offer from privately held Kuva Labs, Inc., valuing the company at up to $6/share.Lisata <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-enters-term-sheet-be-acquired-kuva-labs-400">said</a> that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement whereby Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash. In addition, Lisata shareholders will be entitled to up to $2 per share contingent upon the achievement of certain pre-specified milestones.The transaction has been approved by the board of both companies and Lisata and Kiuva intend to enter into a definitive purchase agreement before Feb 27, Lisata said.The $4 upfront purchase price represents a premium of about 85% from the stock’s closing price on Tuesday.<h2 class="st-heading-2">Lisata’s Pipeline</h2>Lisata’s lead product candidate Certepetide is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively.In November 2024, Kuva had licensed Certepetide as a targeting and enhanced delivery agent to be used with its NanoMark platform technology. The NanoMark platform enables selective imaging of solid tumors with high contrast and spatial resolution, facilitating faster and more accurate diagnosis and treatment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LSTA stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that they are not selling their shares for below $8.<stembedurl>https://www.stocktwits.com/iNeedMillions/message/642431338</stembedurl>Another wondered if some other company would make a higher bid for Lisata.<stembedurl>https://www.stocktwits.com/Defen/message/642409160</stembedurl><a href="https://stocktwits.com/symbol/LSTA">LSTA stock</a> has gained 4% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-dismisses-rumors-of-1700-layoffs-at-german-gigafactory-report/cmUDDUFR4fV">Tesla Dismisses Rumors Of 1700 Layoffs At German Gigafactory: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lisata Shares Nearly Double On Buyout Offer: Here Are The Details

Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.

Equity

Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.


All-Cash Buyout Sparks Breakout Move in Biotech Name

Mergers and acquisitions continue to reshape the biotech landscape as larger and better-capitalized players look to secure promising clinical assets earlier in the development cycle. For small and microcap biotech companies, these deals often arrive suddenly, with premium valuations reflecting not just current data but the long-term strategic value of novel platforms and differentiated pipelines. When that happens, the market tends to respond quickly.Shares of Lisata Therapeutics, Inc. (NASDAQ: LSTA) are surging Wednesday after the company announced it has entered into a binding term sheet ...

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its product, Certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

Current Price	$3.19
Prev Close	$3.13
Open	$3.22
Dividend Yield	0.00%
50-Day Moving Average	$4.40
Beta	0.65
Avg. Volume	95,871.38
PE Ratio	-1.64

52-Week High	$5.07
52-Week Low	$1.81
Market Capitalization	$28.5M
EPS (Annual)	-$1.91
Price to Book	1.86
Revenue Per Employee	$8,095.24

LSTA
Lisata Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LSTA News

LSTALisata Therapeutics Inc